The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities

Journal of Viral Hepatitis

Volumn 25, Issue 7, 2018, Pages 791-801

  Cortesi, P A ^a   Belli, L S ^a,b   Facchetti, R ^a   Mazzarelli, C ^b   Perricone, G ^b   De Nicola, S ^b   Cesana, G ^a   Duvoux, C ^c   Mantovani, L G ^a   Strazzabosco, M ^a,d  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c HENRI MONDOR HOSPITAL   (France)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cost effectiveness; direct acting antiviral agents; hepatitis C; liver transplantation

Indexed keywords

ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; HEPATITIS C; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; SENSITIVITY ANALYSIS; SIMULATION; CHRONIC HEPATITIS C; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TIME FACTOR;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS;

EID: 85043377271     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12877     Document Type: Article

References (28)

1. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148:100-107.
2. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649-659.
3. Levitsky J, Verna EC, O'Leary JG, et al. Perioperative ledipasvir-sofosbuvir for HCV in liver-transplant recipients. N Engl J Med. 2016;375:2106-2108.
4. Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65:524-531.
5. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375-2382.
6. Cortesi PA, Mantovani LG, Ciaccio A, et al. Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis. Am J Transplant. 2015;15:1817-1826.
7. Mantovani LG, Cortesi PA, Strazzabosco M. Effective but costly: how to tackle difficult trade-offs in evaluating health improving technologies in liver diseases. Hepatology. 2016;64:1331-1342.
8. Caro JJ, Briggs AH, Siebert U, Kuntz KM, ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices-overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1.Med Decis Making. 2012;32:667-677.
9. Tapper EB, Hughes MS, Buti M, et al. The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C Cirrhosis: a Cost-Effectiveness Analysis. Transplantation. 2017;101:987-995.
10. Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
11. Regione Emilia Romagna. DOCUMENTO DI INDIRIZZO per la definizione delle strategie terapeutiche da applicare sul breve termine per: Nuovi antivirali diretti nella terapia dell'epatite C cronica. Updating September 2016 http://salute.regione.emilia-romagna.it/documentazione/ptr/elaborati/229-epatite-c-cronica-settembre-2016(accessed May 2017)
12. Njei B, McCarty TR, Fortune BE, et al. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2016;44:1090-1101.
13. Ahmed A, Gonzalez SA, Cholankeril G, et al. Treatment of patients waitlisted for liver transplant with an all-oral DAAs is a cost-effective treatment strategy in the United States. Hepatology. 2017;66:46-56.
14. Chhatwal J, Samur S, Kues B, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2016;65:777-788.
15. Jang JW, Choi JY, Kim YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus–related cirrhosis. Hepatology. 2015;61:1809-1820.
16. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57:675-688.
17. Vitale A, Spolverato G, Burra P, et al. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. Transpl Int. 2015;28:1055-1065.
18. Alazawi W, Cunningham M, Dearden J, et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32:344-355.
19. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32:673-684.
20. Prieto M, Berenguer M, Rayón JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29:250-256.
21. Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000;32:852-858.
22. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579-587.
23. Cadaha V, Gonzalez-Dieguez ML, Alonso P, et al. Exclusions and deaths on the liver transplant waiting list. Transplant Proc. 2010;42:622-624.
24. Bruno S, Zuin M, Crosignani A, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol. 2009;104:1147-1158.
25. Linas BP, Barter DM, Morgan JR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015;162:619-629.
26. Angelico M, Cillo U, Fagiuoli S, et al. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis. 2011;43:155-164.
27. Firpi RJ, Clark V, Soldevila-Pico C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 2009;15:1063-1071.
28. Bodzin AS, Lunsford KE, Markovic D, Harlander-Locke MP, Busuttil RW, Agopian VG. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics. Ann Surg. 2017;266:118-125.